On-Demand Cell and Tissue Biologics for Mass Casualty Response

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-18-C-0007
Agency Tracking Number: A2-6795
Amount: $428,127.33
Phase: Phase II
Program: SBIR
Solicitation Topic Code: A16-050
Solicitation Number: 2016.0
Timeline
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-03-16
Award End Date (Contract End Date): 2019-03-15
Small Business Information
310 Georgia St., Vallejo, CA, 94590
DUNS: 079674686
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 Xiaoxi Wei
 (716) 861-1508
 xwei@x-therma.com
Business Contact
 Mark Kline
Phone: (814) 331-1109
Email: mkline@x-therma.com
Research Institution
N/A
Abstract
A key bottleneck to be addressed in regenerative medicine is hypothermic preservation of cells and tissues, which has been shown to extend survival of cell and tissue-based therapies by decreasing ischemic effect. However, current preservation technology is aged, toxic and less effective than desired, hindering efforts to repair traumatic injury and chronic disease using new cell and tissue-based therapies. The proposed extracellular-like cryopreservation matrix technology (a cryomatrix) supports the critical preservation infrastructure needed to enable post-delivery assurance of therapy viability, function, and efficacy for precious biologics such as bone marrow.Phase I engineered first-of-its-kind biomimetic cryomatrices that are thermoresponsive and biocompatible to cryopreserve biologics. These non-toxic DMSO-, protein- and serum-free cryomatrices and the chemistry governing its high cell recovery performance after storage at -80C is made possible by bioinspired chemistry. A Phase II R&D effort will advance chemical efforts to extend the capabilities of these cryomatrices and maximize their technological impact in biobanking.The primary goal is to establish this technology for long-term storage of critical blood and tissue biologics. Cryopreserved, transported, and thawed biologics will be transplanted into an immunocompromised murine model and assessed for engraftment at various time points.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government